Moreover, miR-126 has been proposed as a therapeutic agent to treat undifferentiated thyroid carcinoma by targeting the PIK3R2 gene and reducing p85β protein translation while lowering AKT kinase activity [15]. The gene discussed is PIK3R2; the disease is thyroid gland undifferentiated (anaplastic) carcinoma.